Splash Beverage Group Announces FDA Regulatory Milestone for CannEpil

What Happened
Splash Beverage Group, Inc. filed a Form 8‑K on August 25, 2026, disclosing that it achieved the first FDA Regulatory Milestone for its CannEpil® veterinary development program under its collaboration agreement with Lupvindal Biosciences Ltd. The company said this milestone formally initiates the regulatory process for developing CannEpil as an investigational veterinary pharmaceutical. The disclosure was made via a press release furnished as Exhibit 99.1 to the 8‑K (Regulation FD Disclosure, Item 7.01).

Key Details

• Date of filing: August 25, 2026 (Form 8‑K, Item 7.01).
• Program: CannEpil® veterinary development program.
• Partner: Collaboration agreement with Lupvindal Biosciences Ltd.
• Milestone: Described as the "first FDA Regulatory Milestone," which formally initiates the regulatory process for CannEpil as an investigational veterinary pharmaceutical. Press release attached as Exhibit 99.1.

Why It Matters
This filing documents a concrete regulatory step in Splash Beverage Group’s CannEpil veterinary program, marking movement from pre‑regulatory stages into the formal FDA regulatory process. For investors, the disclosure is a factual update on program progress and the company’s collaboration with Lupvindal; it may be useful to monitor future filings and press releases for additional regulatory, clinical, or commercial developments.